Campbell Newman Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Campbell Newman Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.32M	Buy	44,808 +738	+2%	+$37.6K	0.19%	56
2025 Q4	$2.19M	Sell	44,070 -1,690	-4%	-$82.2K	0.16%	62
2025 Q3	$2.19M	Buy	45,760 +185	+0.4%	+$7.45K	0.16%	67
2025 Q2	$1.44M	Buy	45,575 +3,019	+7%	+$96.8K	0.11%	84
2025 Q1	$1.39M	Sell	42,556 -196	-0.5%	-$6.95K	0.12%	80
2024 Q4	$1.55M	Sell	42,752 -164	-0.4%	-$5.78K	0.12%	77
2024 Q3	$1.34M	Sell	42,916 -710	-2%	-$22.2K	0.1%	85
2024 Q2	$1.17M	Buy	43,626 +91	+0.2%	+$2.64K	0.09%	85
2024 Q1	$1.48M	Buy	43,535 +1,154	+3%	+$34.4K	0.12%	75
2023 Q4	$1.23M	Buy	42,381 +26	+0.1%	+$689	0.11%	82
2023 Q3	$1.17M	Buy	42,355 +16,476	+64%	+$502K	0.11%	83
2023 Q2	$778K	Buy	25,879 +564	+2%	+$19.7K	0.07%	93
2023 Q1	$917K	Buy	25,315 +226	+0.9%	+$8.69K	0.09%	88
2022 Q4	$895K	Buy	25,089 +791	+3%	+$27.5K	0.09%	88
2022 Q3	$822K	Buy	24,298 +583	+2%	+$19K	0.09%	84
2022 Q2	$686K	Buy	23,715 +1,019	+4%	+$29.2K	0.07%	97
2022 Q1	$734K	Buy	22,696 +443	+2%	+$13.6K	0.07%	96
2021 Q4	$649K	Buy	22,253 +584	+3%	+$17.7K	0.06%	102
2021 Q3	$578K	Buy	21,669 +1,030	+5%	+$27.6K	0.06%	103
2021 Q2	$635K	Buy	20,639 +1,127	+6%	+$34.6K	0.06%	104
2021 Q1	$511K	Buy	19,512 +912	+5%	+$25.5K	0.05%	109
2020 Q4	$468K	Buy	18,600 +1,381	+8%	+$29.7K	0.05%	109
2020 Q3	$359K	Buy	17,219 +307	+2%	+$6.97K	0.05%	112
2020 Q2	$402K	Buy	16,912 +148	+0.9%	+$3.27K	0.06%	106
2020 Q1	$302K	Sell	16,764 -795	-5%	-$16.7K	0.05%	107
2019 Q4	$416K	Sell	17,559 -25	-0.1%	-$607	0.06%	111
2019 Q3	$483K	Sell	17,584 -137	-0.8%	-$4.06K	0.07%	106
2019 Q2	$586K	Buy	17,721 +1,154	+7%	+$39.5K	0.09%	96
2019 Q1	$581K	Buy	16,567 +397	+2%	+$14.8K	0.09%	96
2018 Q4	$537K	Buy	16,170 +1,669	+12%	+$71.8K	0.09%	94
2018 Q3	$730K	Buy	14,501 +750	+5%	+$37K	0.11%	82
2018 Q2	$823K	Buy	13,751 +633	+5%	+$32.8K	0.13%	69
2018 Q1	$601K	Buy	13,118 +567	+5%	+$23.7K	0.1%	90
2017 Q4	$500K	Buy	12,551 +2,301	+22%	+$90.9K	0.08%	92
2017 Q3	$410K	Buy	10,250 +1,312	+15%	+$56.8K	0.07%	93
2017 Q2	$385K	Buy	8,938 +413	+5%	+$14.7K	0.07%	91
2017 Q1	$267K	Buy	+8,525	New	+$228K	0.05%	102

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Campbell Newman Asset Management's SUPN Position: Q1 2026 in Review

Campbell Newman Asset Management increased its Supernus Pharmaceuticals (SUPN) stake by 1.7% in Q1 2026, buying an estimated $37.6K and bringing the position to 44,808 shares worth $2.32M. The position accounts for 0.19% of the portfolio, ranked #56.

Campbell Newman Asset Management first reported a position in SUPN in Q1 2017 and has held it in 37 quarters since. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

Campbell Newman Asset Management held 44,808 shares of Supernus Pharmaceuticals worth $2.32M as of Q1 2026.
Campbell Newman Asset Management bought 738 Supernus Pharmaceuticals shares in Q1 2026, an estimated $37.6K.
Supernus Pharmaceuticals made up 0.19% of Campbell Newman Asset Management's portfolio in Q1 2026, its #56 holding.
Campbell Newman Asset Management first reported a position in Supernus Pharmaceuticals in Q1 2017 and has held it in 37 quarters since.
327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Campbell Newman Asset Management's 13F filing for Q1 2026, filed 16 Apr 2026.